Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations


January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cleveland, J.C., Cigarroa, J.E., et al. (2014) 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 14, S0735-S1097.

has been cited by the following article:

  • TITLE: Novel Therapeutic Options for the Treatment of Nonvalvular Atrial Fibrillation

    AUTHORS: Rupal Patel Mansukhani, Lucio R. Volino

    KEYWORDS: Atrial Fibrillation, Dabigatran, Rivaroxaban, Apixiaban

    JOURNAL NAME: Pharmacology & Pharmacy, Vol.5 No.11, October 29, 2014

    ABSTRACT: Objective: To review the literature for the emerging oral anticoagulants, dabigatran, rivaroxaban, and apixaban currently available in the United States. Data Source: A literature review was performed in MEDLINE (1947–July 2014) using the keywords atrial fibrillation AND dabigatran OR rivaroxaban OR apixaban. The references identified from the literature review were then evaluated. All of the literature retrieved from MEDLINE that was published as an original clinical trial was included in this review. Other pertinent articles published related to the original clinical trials were also considered. The references included in this review were limited to studies conducted in humans and written in the English language. Conclusion: The new oral anticoagulant agents have demonstrated benefit over warfarin. The pharmacologic profiles of the newer agents are predictable, with rapid onsets of action. The newer agents are also more convenient for patients since they do not require regular INR monitoring. Although there are many advantages to the newer agents, a patient evaluation must be considered prior to initiating them.